bpc 157 human clinical trials safety dosing bpc-157 dosage BPC-157 (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or BPC-157 as an Investigational Peptide
Description
BPC-157 has demonstrated neuroprotective properties, protecting nerve cells from damage and supporting their regeneration

A new human study followed patients with chronic knee pain through a structured BPC-157 protocol and tracked outcomes at the 6 and 12-month marks
Those with severe organ dysfunction should consult physicians before use
It is not approved by any regulatory authority for human use
